PITTSBURGH, Oct. 3 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that Cheryl Fossum Graham, M.D., F.C.P., has joined the company as senior vice president of regulatory and development strategy.
Dr. Graham brings to Knopp 28 years of experience in public and commercial regulatory leadership, including senior positions with the Food and Drug Administration and responsibility for global regulatory affairs at Pfizer Inc. In her capacity at Knopp, Dr. Graham leads development strategy as well as safety and regulatory activities associated with KNS-760704, an orally administrated small molecule in development by Knopp for amyotrophic lateral sclerosis (ALS).
"Dr. Graham's experience, judgment, and track record for innovation bring tremendous benefits to Knopp," said Michael Bozik, M.D., president and chief executive officer. "She's essential to our mission of accelerating the development of a safe and effective therapy for ALS and other serious neurological diseases."
Prior to joining Knopp, Dr. Graham spent six years in senior leadership
positions at Pfizer Inc., including as senior vice president of Pfizer
Global Research and Development and as director of worldwide regulatory
affairs. Previously she served as vice president of clinical and regulatory
research at Quintiles Inc. From 1979 to 1993, Dr. Graham held numerous
positions with the U.S. Food and Drug Administration, including as acting
director, deputy director and group leader in the Drug Marketing and
Cardio-Renal Drug Products divisions of the FDA Center for Drug Evaluation
and Research (CDER). She also served as regulatory scientist at Hyman,
Phelps & McNamara, a Washington, DC- based food and drug law firm. She
holds degrees in biology/chemistry, pharmacy, microbiology, and medicine
from the University of New Mexico,
|SOURCE Knopp Neurosciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved